Kenya will begin deploying a new long acting HIV-prevention injection in March, marking a major step in the country’s fight against the virus as African governments adjust to changing US foreign aid priorities. The drug, lenacapavir, made by Gilead Sciences, has shown over 99.9% effectiveness in preventing HIV transmission with just two injections per year. Kenya received an initial 21,000 doses this week through an agreement with the Global Fund. Health Minister Aden Duale said the first phase will start in early March across 15 counties, with another 12,000 doses expected by April. The United States has also pledged 25,000 additional doses to Kenya, where HIV prevalence stands at 3.7%.
The rollout comes amid uncertainty over international health funding following policy shifts under US President Donald Trump. Eastern and southern Africa together account for more than half of the world’s 40.8 million people living with HIV, heightening concerns over reduced external support. In December, Kenya signed a $2.5 billion bilateral health agreement with Washington, the first major pact since the dismantling of USAID. Under the deal, the US will provide $1.6 billion over five years, while Kenya commits $850 million, gradually taking on a larger share of health financing. The agreement, however, is facing a legal challenge from a Kenyan senator who argues it violates constitutional provisions.
